Form 4: BioCryst Legal Officer Sells Shares Under 10b5-1 Plan

BioCryst Pharmaceuticals' Chief Legal Officer, Alane P. Barnes, reported the sale of 21,210 common shares under a pre-arranged 10b5-1 trading plan, alongside a tax-related disposition.

Summary

• Alane P. Barnes, Chief Legal Officer of BIOCRYST PHARMACEUTICALS INC (BCRX), reported two transactions involving the company's common stock.
• On December 12, 2025, 8,540 shares were disposed of at a price of $7.57 per share. This transaction represents shares withheld by the issuer to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units and is not a discretionary sale by the reporting person.
• Following this tax-related disposition, Barnes beneficially owned 336,936 shares.
• On December 15, 2025, an additional 21,210 shares were sold at a price of $7.65 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025, indicating it was an automatic and non-discretionary transaction.
• After both transactions, Barnes' direct beneficial ownership of common stock stands at 315,726 shares.

Sentiment

Score: 5

Explanation: The transactions reported are routine insider dispositions, including shares withheld for tax obligations and a pre-scheduled sale under a 10b5-1 plan. These are generally considered non-discretionary and do not typically signal a change in management's outlook on the company's prospects, leading to a neutral sentiment.

Positives

• The sale of 21,210 shares was conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests it was not a discretionary, market-timing decision based on new material information.
• The disposition of 8,540 shares was solely for tax withholding obligations related to vested restricted stock units, a routine event that does not represent a direct sale by the officer.

Negatives

• The Chief Legal Officer reduced her direct beneficial ownership of common stock by a total of 29,750 shares (8,540 shares for tax withholding and 21,210 shares from the 10b5-1 plan).
• Even though the sale of 21,210 shares was pre-planned, it still represents a reduction in insider holdings.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This filing reports routine insider transactions and does not provide broader industry context or trends.

Related Party Transactions

• The reported transactions involve the Chief Legal Officer, Alane P. Barnes, who is considered a related party to BIOCRYST PHARMACEUTICALS INC.

Stakeholder Impact

• Shareholders: The reduction in insider ownership, even if pre-planned, could be perceived by some as a minor negative, though the 10b5-1 plan mitigates concerns about discretionary selling. The tax withholding is a standard event for equity compensation and has no significant impact.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this filing.

Key Dates

Recommendation

The reported transactions by the Chief Legal Officer are largely non-discretionary. The disposition for tax withholding is a standard event for vested equity, and the sale under a Rule 10b5-1 plan indicates a pre-scheduled liquidation of shares rather than a market-timing decision based on new material information. Therefore, these transactions do not provide a strong signal to alter an existing investment position, warranting a 'hold' recommendation.

Keywords

BIOCRYST PHARMACEUTICALS INC, BCRX, Insider Trading, Form 4, Alane P. Barnes, Chief Legal Officer, Stock Sale, 10b5-1 Plan, Restricted Stock Units, Tax Withholding